SCHEMBL275355

SCHEMBL275355

O=C1Nc2cc(Cl)ccc2C1=Cc1cccc(F)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 3/20 0.58
PDGFRB P09619 2/20 0.52
TUBB4A P04350 2/20 0.50
TUBB P07437 2/20 0.50
TUBA3C P0DPH7 2/20 0.50
TUBA1B P68363 2/20 0.50
TUBA4A P68366 2/20 0.50
TUBB4B P68371 2/20 0.50
TUBB3 Q13509 2/20 0.50
TUBB2A Q13885 2/20 0.50
TUBB8 Q3ZCM7 2/20 0.50
TUBA3E Q6PEY2 2/20 0.50
TUBA1A Q71U36 2/20 0.50
TUBA1C Q9BQE3 2/20 0.50
TUBB6 Q9BUF5 2/20 0.50
TUBB2B Q9BVA1 2/20 0.50
TUBB1 Q9H4B7 2/20 0.50
PLK4 O00444 1/20 0.50
PLK1 P53350 1/20 0.50
KDR P35968 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL279162 1.00 LRRK2 (0.58) LRRK2PDGFRBTUBB4ATUBBTUBA3C
SCHEMBL275354 1.00 LRRK2 (0.58) LRRK2PDGFRBTUBB4ATUBBTUBA3C
SCHEMBL13929117 0.91 PDGFRB (0.60) LRRK2PDGFRBPLK4PLK1KDR
SCHEMBL4723150 0.91 PDGFRB (0.60) LRRK2PDGFRBPLK4PLK1KDR
SCHEMBL29443853 0.90 LRRK2 (0.65) LRRK2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL250593 0.90 LRRK2 (0.65) LRRK2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL250592 0.90 LRRK2 (0.65) LRRK2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL8205160 0.90 LRRK2 (0.65) LRRK2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL14674926 0.90 LRRK2 (0.73) LRRK2PDGFRBPSEN1PSEN2APH1B
SCHEMBL14674927 0.90 LRRK2 (0.73) LRRK2PDGFRBPSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8742121-B2 Process for the preparation of small molecule inhibitors of MDM2 and intermediates used therein THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-06-03 US claimed
US-20130035364-A1 BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE NATIONAL UNIVERSITY OF SINGAPORE (SG) 2013-02-07 US claimed
US-20130030173-A1 PROCESS FOR THE PREPARATION OF SMALL MOLECULE INHIBITORS OF MDM2 AND INTERMEDIATES USED THEREIN THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2013-01-31 US claimed
US-8877946-B2 Benzylidene-indolinone compounds and their medical use NATIONAL UNIVERSITY OF SINGAPORE (SG) 2014-11-04 US disclosed
US-8877946-B2 Benzylidene-indolinone compounds and their medical use NATIONAL UNIVERSITY OF SINGAPORE (SG) 2014-11-04 US disclosed
US-20130035364-A1 BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE NATIONAL UNIVERSITY OF SINGAPORE (SG) 2013-02-07 US disclosed
US-20130035364-A1 BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE NATIONAL UNIVERSITY OF SINGAPORE (SG) 2013-02-07 US disclosed
US-20130035364-A1 BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE NATIONAL UNIVERSITY OF SINGAPORE (SG) 2013-02-07 US disclosed
US-8217051-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-07-10 US disclosed
US-8217051-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-07-10 US disclosed
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
WO-2010094622-A1 3, 3' -SPIROINDOLINONE DERIVATIVES AS ANTICANCER AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
WO-2010094622-A1 3, 3' -SPIROINDOLINONE DERIVATIVES AS ANTICANCER AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210674-A1 Spiroindolinone Derivatives HOFFMANN-LA ROCHE INC. 2010-08-19 US disclosed
US-20100210674-A1 Spiroindolinone Derivatives HOFFMANN-LA ROCHE INC. 2010-08-19 US disclosed
US-7638548-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-12-29 US disclosed
WO-2009077357-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed
US-20080114013-A1 SPIROINDOLINONE DERIVATIVES LIU JIN-JUN 2008-05-15 US disclosed
WO-2008055812-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156610-A1 Spiroindolinone Derivatives SDHA, AR, XPOT LRRK2 1100/4885PDGFRB 1789/4885TUBB4A 414/4885
US-20130035364-A1 BENZYLIDENE-INDOLINONE COMPOUNDS AND THEIR MEDICAL USE ERBB2, ABL1, IGF1R LRRK2 19/4885PDGFRB 11/4885TUBB4A 311/4885
US-20100210674-A1 Spiroindolinone Derivatives RCC2, PKD1, SIK2 LRRK2 870/4885PDGFRB 1738/4885TUBB4A 412/4885
US-20130030173-A1 PROCESS FOR THE PREPARATION OF SMALL MOLECULE INHIBITORS OF MDM2 AND INTERMEDIATES USED THEREIN TP53, MDM2, CDKN1A LRRK2 963/4885PDGFRB 2992/4885TUBB4A 2763/4885
US-20080114013-A1 SPIROINDOLINONE DERIVATIVES RB1, XPOT, PDK2 LRRK2 267/4885PDGFRB 1904/4885TUBB4A 292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.